HeartBeam Expands Board with CEO Robert Eno's Appointment

HeartBeam Inc. (NASDAQ: BEAT) has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members. Eno, who joined the company as president in January 2023 and became CEO in October 2024, brings over three decades of medtech leadership experience to the role.

The appointment comes at a critical time for HeartBeam, as the company prepares for the commercial launch of its 3D ECG technology. The company is pending FDA clearance for its 12-lead ECG synthesis software, which represents a potential significant advancement in cardiac care technology.

Eno's extensive background in launching disruptive technologies could prove instrumental in HeartBeam's strategic positioning. The company aims to revolutionize cardiac health management by developing a cable-free 12-lead ECG platform capable of capturing the heart's electrical signals from three dimensions.

This technology is designed to enable physicians to identify cardiac health trends and acute conditions outside traditional medical facilities, potentially transforming how heart health is monitored and managed. With 13 U.S. and 4 international patents, HeartBeam is positioning itself as an innovative player in personalized cardiac care.

The board expansion and Eno's appointment suggest the company is preparing for significant growth and commercialization of its groundbreaking cardiac monitoring technology.